Drug General Information
Drug ID	D04BPS
Former ID	DIB001531
Drug Name	Naveglitazar
Synonyms	LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand
Drug Type	Small molecular drug
Indication	Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]		Phase 2	[521566]
Company	Ligand Pharmaceuticals
Structure		Download 2D MOL 3D MOL
Formula	C25H26O6
Canonical SMILES	C(=O)([C@H](Cc1ccc(cc1)OCCCOc1ccc(Oc2ccccc2)cc1)OC)O
PubChem Compound ID	9888484
Target and Pathway
Target(s)	Peroxisome proliferator activated receptor gamma	Target Info	Modulator	[528458]
	Peroxisome proliferator activated receptor alpha	Target Info	Modulator	[528458]
KEGG Pathway	PPAR signaling pathway
	AMPK signaling pathway
	Osteoclast differentiation
	Huntington's disease
	Pathways in cancer
	Transcriptional misregulation in cancer
	Thyroid cancerhsa03320:PPAR signaling pathway
	cAMP signaling pathway
	Adipocytokine signaling pathway
	Glucagon signaling pathway
	Non-alcoholic fatty liver disease (NAFLD)
	Hepatitis C
NetPath Pathway	IL1 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
	Leptin Signaling Pathway
PANTHER Pathway	CCKR signaling map ST
Pathway Interaction Database	Noncanonical Wnt signaling pathway
	Calcineurin-regulated NFAT-dependent transcription in lymphocytes
	Signaling events mediated by HDAC Class I
	RXR and RAR heterodimerization with other nuclear receptor
	Regulation of retinoblastoma proteinrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor
Reactome	PPARA activates gene expression
	Transcriptional regulation of white adipocyte differentiation
	Nuclear Receptor transcription pathwayR-HSA-1368082:RORA activates gene expression
	BMAL1:CLOCK,NPAS2 activates circadian gene expression
	YAP1- and WWTR1 (TAZ)-stimulated gene expression
	Transcriptional activation of mitochondrial biogenesis
	Activation of gene expression by SREBF (SREBP)
	Nuclear Receptor transcription pathway
	Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
	Circadian Clock
WikiPathways	Wnt Signaling Pathway Netpath
	Nuclear Receptors in Lipid Metabolism and Toxicity
	Differentiation of white and brown adipocyte
	Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
	Transcriptional Regulation of White Adipocyte Differentiation
	Adipogenesis
	SREBP signalling
	Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity
	Nuclear Receptors Meta-Pathway
	Estrogen Receptor Pathway
	PPAR Alpha Pathway
	YAP1- and WWTR1 (TAZ)-stimulated gene expression
	Activation of Gene Expression by SREBP (SREBF)
	SREBF and miR33 in cholesterol and lipid homeostasis
	Circadian Clock
	Nuclear Receptors
References
Ref 521566	ClinicalTrials.gov (NCT00065312) An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes. U.S. National Institutes of Health.
Ref 528458	The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys. Drug Metab Dispos. 2007 Jan;35(1):51-61. Epub 2006 Sep 29.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.